摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-benzylidene-4-methyl-3-oxo-pentanoic acid benzyl ester | 805242-33-5

中文名称
——
中文别名
——
英文名称
2-benzylidene-4-methyl-3-oxo-pentanoic acid benzyl ester
英文别名
4-Methyl-3-oxo-2-[1-phenyl-methylidene]-pentanoic acid benzyl ester;benzyl 2-benzylidene-4-methyl-3-oxopentanoate
2-benzylidene-4-methyl-3-oxo-pentanoic acid benzyl ester化学式
CAS
805242-33-5
化学式
C20H20O3
mdl
——
分子量
308.377
InChiKey
OGFWQFLJYXWCBF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    397.5±12.0 °C(Predicted)
  • 密度:
    1.123±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    23
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted pyrrole derivatives
    申请人:——
    公开号:US20040102511A1
    公开(公告)日:2004-05-27
    The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as, pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.
    本发明涉及取代吡咯生物,可用作3-羟基-3-甲基戊二酸辅酶AHMG-CoA)还原酶抑制剂。本文披露的化合物可作为降胆固醇剂,并可用于治疗胆固醇相关疾病和相关症状。提供了制备披露化合物的过程,以及包含披露化合物的药物组合物,以及治疗胆固醇相关疾病和相关症状的方法。
  • [EN] SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS<br/>[FR] DERIVES DE PYRROLE SUBSTITUES UTILES COMME INHIBITEURS DE HMG-COA REDUCTASE
    申请人:RANBAXY LAB LTD
    公开号:WO2004105752A1
    公开(公告)日:2004-12-09
    The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R2, R4 and R5 is a heterocycle and with the further provision that if R2 is not a heterocycle then either R4 or R5 alone is not unsubstituted pyridyl, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.
    本发明涉及式(I)的取代吡咯生物,其中(Y),条件是R2、R4和R5中的一个是杂环,并且进一步规定如果R2不是杂环,则R4或R5中的任一者不是未取代的吡啶基,这些衍生物可用作3-羟基-3-甲基戊二酰辅酶AHMG-CoA)还原酶抑制剂。本文披露的化合物可以作为降低胆固醇的药剂,并可用于治疗与胆固醇相关的疾病及相关症状。提供了用于制备披露的化合物的方法,以及含有披露的化合物的药物组合物和治疗与胆固醇相关的疾病及相关症状的方法。
  • PROCESS FOR THE PREPARATION OF ATORVASTATIN
    申请人:Sattigeri Jitendra A.
    公开号:US20090209612A1
    公开(公告)日:2009-08-20
    The invention relates to processes for the preparation of atorvastatin. Atorvastatin is known by the chemical name [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid. The hemi-calcium salt of atorvastatin is useful as an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). The invention also relates to pharmaceutical compositions that include the atorvastatin or a pharmaceutically acceptable salt thereof and to use of said compositions for treating hypolipidemia, hypocholesterolemia and atherosclerosis.
    本发明涉及阿托伐他汀的制备过程。阿托伐他汀化学名称为[R-(R*,R*)]-2-(4-氟苯基)-β,δ-双羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基基)羰基]-1H-吡咯烷-1-庚酸阿托伐他汀的半盐对于酶3-羟基-3-甲基戊二酰辅酶A还原酶(HMG-CoA还原酶)的抑制作用是有用的。本发明还涉及包括阿托伐他汀或其药学上可接受的盐的制药组合物,并且涉及使用该组合物治疗低脂血症,低胆固醇血症和动脉粥样硬化。
查看更多